SGLT2 inhibitors, antidiabetcs with strong cardio and nephroprotection
Chronic kidney disease (CKD) is a major public health problem. About 10% of the adult population has CKD. The most common cause is diabetic nephropathy (DN). In addition to DN, patients with diabetes may have other causes of CKD, i. e. diabetic kidney disease (DKD). Therefore, over 40% of patients with type 2 diabetes have some form of DKD. Less than 10 years ago, clinical use of new antidiabetics, SGLT2 inhibitors, was introduced. In addition to good antidiabetic effects, new drugs soon proved to have strong cardio and nephroprotective effects in patients with type 2 diabetes. Also, the results of recent clinical studies suggest that they may be useful for people with non-diabetic CKD.
Key words:
diabetes mellitus; diabetic kidney disease; SGLT2 inhibitors